CalciMedica, Inc. announced the appointment of Stephen Bardin as its new Chief Financial Officer, effective November 7, 2024. Mr. Bardin will succeed Daniel Geffken, who served as Interim Chief Financial Officer and will depart upon the filing of the company's third-quarter financial statements. This leadership change aims to bolster CalciMedica's financial strategy and operations.
Mr. Bardin brings extensive experience in capital raising, corporate development, and strategic finance, having most recently served as CFO of atai Life Sciences. His prior roles include nearly three years at BridgeBio Pharma, Inc., where he helped raise over $2 billion through various financing transactions. His expertise is expected to be invaluable as CalciMedica advances its clinical-stage pipeline.
Rachel Leheny, Ph.D., Chief Executive Officer of CalciMedica, stated that Mr. Bardin has been advising the company on strategic matters for several months and was critical in executing a recent public financing. His full-time appointment is anticipated to further strengthen the company's ability to fund and progress its lead candidate, Auxora, through key development stages.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.